Leading brokers name 3 ASX shares to buy today

The ResMed Inc (ASX:RMD) share price is one of three that leading brokers have tipped to climb higher…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

Many of Australia's leading brokers are back in the office again after the Christmas break and have been busy adjusting their recommendations to account for new data and developments.

Three shares that have fared well and been given buy ratings are listed below. Here's why they are in favour with brokers:

Pilbara Minerals Ltd (ASX: PLS)

A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and $1.20 price target on this lithium miner's shares after its update last week. The broker appears to be pleased that strong demand has led to the company investigating the need for further processing expansions. And although its equity raising is expected to dilute earnings per share, the broker remains positive on Pilbara Minerals due to positive long term demand. While I do like Pilbara Minerals, I intend to see how lithium prices fare in 2019 before considering an investment.

ResApp Health Ltd (ASX: RAP)

According to a note out of Morgans, its analysts have a (high risk) add rating and 24 cents price target on this digital health company's shares. The broker made the move after ResApp announced that it has submitted its CE Mark technical file that is required to allow commercial sales to commence. In addition to this, the broker notes that there are two potential catalysts on the horizon that could move its shares. These are the outcomes of its adult respiratory study in Australia and the clinical adjudication for croup.

ResMed Inc (ASX: RMD)

Analysts at Morgan Stanley have retained their overweight rating and increased the price target on its U.S. shares to US$126 (approximately $17.70 for its ASX listed CDIs). According to the note, the broker has reviewed the healthcare sector ahead of earnings season and sees no reason why ResMed's strong earnings growth trajectory will be disrupted. In light of this, the broker believes that its rich valuation will remain in place for some time to come. I agree with Morgan Stanley on ResMed and think it is one of the best buy and hold options on the local market right now.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Broker Notes

2 ASX 200 shares Macquarie thinks will return nearly 30%

These two companies could be worth a closer look.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Ord Minnett says these ASX 300 shares are buys

The broker is feeling bullish about these shares right now.

Read more »

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.
Broker Notes

3 ASX shares upgraded by Morgans to buy ratings

Let's see why the broker has turned positive on these shares.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing start to the trading week.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to buy these shares.

Read more »

Wooden blocks spelling rebound with coins on top.
Broker Notes

Can Life360 shares recover from the AI fuelled sell-off?

A leading expert looks into the AI-driven pressure hitting Life360 shares.

Read more »

An engineer takes a break on a staircase and looks out over a huge open pit coal mine as the sun rises in the background.
Broker Notes

Up 49% in a year, should you buy BHP shares for their 'stability and income'?

A leading expert delivers his forecast for BHP’s fast-rising shares.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Buy, hold, sell: Pro Medicus, Life360, A2 Milk shares

Expert analysts reveal their latest recommendations on 3 ASX 200 stocks.

Read more »